Soufflé Raises $135 Million for Extrahepatic RNA Delivery
Soufflé Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group. The company plans to fund three lead programs spanning facioscapulohumeral muscular dystrophy, heart failure, and an undisclosed muscle and metabolic target,…
